Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Cellular Stiffness as a Novel Stemness Marker in the Corneal Limbus.

Bongiorno T, Chojnowski JL, Lauderdale JD, Sulchek T.

Biophys J. 2016 Oct 18;111(8):1761-1772. doi: 10.1016/j.bpj.2016.09.005.

2.

Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.

Montanari F, Cseke A, Wlcek K, Ecker GF.

SLAS Discov. 2017 Jan;22(1):86-93. doi: 10.1177/1087057116657513. Epub 2016 Jul 11.

3.

Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P-Glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).

Schwarz T, Montanari F, Cseke A, Wlcek K, Visvader L, Palme S, Chiba P, Kuchler K, Urban E, Ecker GF.

ChemMedChem. 2016 Jun 20;11(12):1380-94. doi: 10.1002/cmdc.201500592. Epub 2016 Mar 10.

4.

Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABCG sequences.

Haider AJ, Cox MH, Jones N, Goode AJ, Bridge KS, Wong K, Briggs D, Kerr ID.

Biosci Rep. 2015 Jul 17;35(4). pii: e00241. doi: 10.1042/BSR20150150.

5.

ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.

Leccia F, Del Vecchio L, Mariotti E, Di Noto R, Morel AP, Puisieux A, Salvatore F, Ansieau S.

Mol Cancer. 2014 Sep 12;13:213. doi: 10.1186/1476-4598-13-213.

6.

ABCG2 is a selectable marker for enhanced multilineage differentiation potential in periodontal ligament stem cells.

Szepesi Á, Matula Z, Szigeti A, Várady G, Szabó G, Uher F, Sarkadi B, Német K.

Stem Cells Dev. 2015 Jan 15;24(2):244-52. doi: 10.1089/scd.2014.0177.

7.

Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70.

Kapoor K, Bhatnagar J, Chufan EE, Ambudkar SV.

J Biol Chem. 2013 Nov 8;288(45):32622-36. doi: 10.1074/jbc.M113.498980. Epub 2013 Sep 24.

8.

Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.

To KK, Tomlinson B.

Br J Pharmacol. 2013 Nov;170(5):1137-51. doi: 10.1111/bph.12367.

9.

The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L, Chen ZS, Ambudkar SV, Baer MR.

Mol Cancer Ther. 2012 Sep;11(9):2033-44. doi: 10.1158/1535-7163.MCT-12-0302. Epub 2012 Jul 9.

10.

Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells.

Shukla S, Schwartz C, Kapoor K, Kouanda A, Ambudkar SV.

Drug Metab Dispos. 2012 Feb;40(2):304-12. doi: 10.1124/dmd.111.042721. Epub 2011 Oct 31.

11.

Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.

Ni Z, Bikadi Z, Shuster DL, Zhao C, Rosenberg MF, Mao Q.

Biochemistry. 2011 Sep 20;50(37):8057-66. doi: 10.1021/bi200573t. Epub 2011 Aug 26.

12.

Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.

Peng H, Qi J, Dong Z, Zhang JT.

PLoS One. 2010 Dec 7;5(12):e15276. doi: 10.1371/journal.pone.0015276.

13.

Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

Ni Z, Bikadi Z, Rosenberg MF, Mao Q.

Curr Drug Metab. 2010 Sep;11(7):603-17. Review.

14.

Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.

Ni Z, Bikadi Z, Cai X, Rosenberg MF, Mao Q.

Am J Physiol Cell Physiol. 2010 Nov;299(5):C1100-9. doi: 10.1152/ajpcell.00160.2010. Epub 2010 Aug 25.

15.

Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease.

Sauna ZE, Okunji C, Hunt RC, Gupta T, Allen CE, Plum E, Blaisdell A, Grigoryan V, Geetha S, Fathke R, Soejima K, Kimchi-Sarfaty C.

PLoS One. 2009 Aug 5;4(8):e6506. doi: 10.1371/journal.pone.0006506.

16.

A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.

Peng H, Dong Z, Qi J, Yang Y, Liu Y, Li Z, Xu J, Zhang JT.

PLoS One. 2009 May 24;4(5):e5676. doi: 10.1371/journal.pone.0005676.

17.

Arginine 383 is a crucial residue in ABCG2 biogenesis.

Polgar O, Ediriwickrema LS, Robey RW, Sharma A, Hegde RS, Li Y, Xia D, Ward Y, Dean M, Ozvegy-Laczka C, Sarkadi B, Bates SE.

Biochim Biophys Acta. 2009 Jul;1788(7):1434-43. doi: 10.1016/j.bbamem.2009.04.016. Epub 2009 May 3.

18.

Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.

Robey RW, Obrzut T, Shukla S, Polgar O, Macalou S, Bahr JC, Di Pietro A, Ambudkar SV, Bates SE.

Cancer Chemother Pharmacol. 2009 Aug;64(3):575-83. doi: 10.1007/s00280-008-0908-2. Epub 2009 Jan 9.

19.

The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant.

Polgar O, Deeken JF, Ediriwickrema LS, Tamaki A, Steinberg SM, Robey RW, Bates SE.

Mol Cell Biochem. 2009 Feb;322(1-2):63-71. doi: 10.1007/s11010-008-9940-0. Epub 2008 Nov 11.

20.

Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter.

Ozvegy-Laczka C, Laczkó R, Hegedus C, Litman T, Várady G, Goda K, Hegedus T, Dokholyan NV, Sorrentino BP, Váradi A, Sarkadi B.

J Biol Chem. 2008 Sep 19;283(38):26059-70. doi: 10.1074/jbc.M803230200. Epub 2008 Jul 21.

Supplemental Content

Support Center